

**NICE GUIDANCE
HEPATITIS B AND C: WAYS TO OFFER AND PROMOTE
TESTING**

5th Meeting of the Programme Development Group

Thursday 27th October 2011

Dee, NICE Offices, City Tower, Manchester

Attendees:	<p><i>Programme Development Group (PDG) Members:</i> Matt Hickman (Chair) Neil Connelly, James Windsor, Erika Duffell, April Wareham, Will Irving, Danny Morris, Kate Drysdale, Daniela De Angelis, Kylie Reed (arrived 10.40), Nat Wright, Emily Kam-Yin Lam, Salim Khakoo, Opal Greyson (arrived 10.45).</p> <p><i>NICE:</i> Antony Morgan (arrived 10.45am), Kay Nolan, James Jagroo, Alastair Fischer, Victoria Axe (arrived 11am), Hilary Chatterton</p> <p><i>Contractors:</i> Lisa Jones (LJMU), Geoff Bates (LJMU), Alec Miners (LSHTM), Natasha Martin (LSHTM), Peter Vickerman (LSHTM), Howard Thomas (Guidance Development Group Chair), Ellie McCoy (LJMU), Anjan Ghosh (LSHTM) (arrived 10.45)</p>
Apologies:	<p><i>PDG Members:</i> Richard Grieve, Deirdre Kelly, Jeremy Jones, Vijay Anand, Cristina Osorio</p>

Author	Victoria Axe
File Ref	Hepatitis PDG 5 – Final Minutes
Version	Final
Audience	PDG members, NICE team, the public (via web publication)

Item		Action
1. Welcome, Introductions	<p>The Chair welcomed the group to the fifth PDG meeting.</p> <p>The Chair noted that apologies had been given from Richard Grieve, Deirdre Kelly, Jeremy Jones, Vijay Anand and Cristina Osorio.</p> <p>The Chair informed the PDG that Helen Wilks had resigned from the committee. The Chair formally thanked Helen for her contribution to the group.</p> <p>The Chair noted that due to issues with trains from London certain PDG members may be delayed.</p> <p>The Chair explained the current order of the day.</p>	
2. Declarations of Interests	<p>The Chair asked if there were any conflicts of interest.</p> <p>Erika Duffell, Matt Hickman, Natasha Martin, Peter Vickerman, Alec Miners and Lisa Jones all declared they are on a European Centre for Disease Control Grant on the cost effectiveness of screening strategies for Hepatitis.</p> <p>Howard Thomas declared he is the Chairman of an Imperial College spin-out company (not involved in hepatitis B). Professor Thomas has also given a lecture on hepatitis C at ID meeting in Berlin 2011 (expenses and honorarium were paid by the industrial sponsor).</p> <p>The Chair confirmed that there were no conflicts that prevented the members of the PDG from continuing the meeting.</p>	
3. Notes of the last meeting	<p>The Chair went through the minutes of the last meeting. The previous actions from these minutes were discussed.</p> <p>The PDG requested that small amendments be made to the minutes but confirmed that they were an accurate account of the last meeting.</p>	
4. Where are we now – meeting overview – running issues	<p>Kay Nolan (KN) gave a presentation reminding the PDG where they currently are in the process and what the next steps will be.</p>	
5. Stigma – discussion of issues	<p>Neil Connelly and April Wareham gave a presentation on stigma based on research and their own experience. It was agreed that they would draft a set of summary statements based on their work and PDG discussions. These would be discussed at a future meeting for inclusion in the draft guidance document.</p>	

6. NICE Hepatitis B Clinical Guideline	<p>Howard Thomas (HT) gave a presentation on the work of the Guideline Development Group (GDG) who are currently developing guidance on Hepatitis B on behalf of the Centre for Clinical Practice at NICE. HT highlighted the future work schedule. Consultation on the draft guidance for this topic is scheduled to take place between February-March 2013.</p> <p>Professor Thomas suggested that Matt Hickman could attend a GDG meeting when the PDG are due to formulate their recommendations.</p> <p>There was also a discussion about how best to ensure that the clinical and public health guidance were complementary.</p>	
7. Effectiveness Review Update– Hepatitis B Presentation and Questions	<p>Lisa Jones gave a presentation on “Findings from a systematic review of the effectiveness and cost effectiveness of interventions aimed at raising awareness and engaging with groups who are at an increase risk of hepatitis B infection”.</p>	
8. Plenary discussion	<p>The PDG were invited to discuss Lisa’s presentation.</p> <p>They were asked to consider recommendations, gaps in evidence, equity issues, terms for glossary and identifying experts to bridge the gaps.</p>	
9. Hepatitis B economic update – presentation of intervention scenario	<p>Alec Miners gave a presentation on “Testing Immigrants to the UK for HBV/HCV”.</p> <p>The PDG discussed the different options for modelling.</p> <p>Action: NICE PPIP Team to contact the Chinese Healthy Living Centre</p> <p>Action: Erika Duffell to give the NICE team contact details for Dr Archana Griffin with regards to finding out more details on the study of screening new practice registrations for blood borne viruses.</p> <p>Action: Alec Miners to list questions for the PDG to respond to in regards to the Hepatitis B model.</p> <p>Action: The PDG should email responses direct to Alec Miners but should copy in Alastair Fischer and Kay Nolan, Antony Morgan.</p>	<p>NICE Team</p> <p>ED</p> <p>AM</p> <p>PDG</p>
10. Effectiveness Review	<p>Lisa Jones gave a presentation on “Findings from a systematic review of the effectiveness and cost-effectiveness of interventions aimed at raising awareness</p>	

<p>Update– Hepatitis C Presentation and Questions</p>	<p>and engaging with groups who are at an increased risk of hepatitis C infection”.</p> <p>The PDG were invited to ask questions about the presentation.</p>	
<p>11. Hepatitis C economic update – presentation of intervention scenario</p>	<p>Natasha Martin (NM) gave a presentation on HCV testing in IDUs. This included a discussion around areas where testing is more prevalent, areas where the yield is higher, possible intervention scenarios and prison testing.</p> <p>Action: Natasha to circulate her slides to the PDG for feedback</p> <p>Action: NM to search for data on location testing in Scotland.</p> <p>Action: Danny Morris to forward papers to the PDG on benefits of HCV testing</p> <p>Will Irving left the meeting at 15.20pm</p> <p>Action: Kate Drysdale to email NM in regards to the costs (in terms of extra appointments etc) for different categories of active drug user.</p> <p>Action: Erica Duffell to email NM a contact name from the British Liver Trust</p>	<p>NM</p> <p>NM</p> <p>DM</p> <p>KD</p> <p>ED</p>
<p>12. Plenary discussion</p>	<p>The PDG were invited to comment on Natasha’s presentation and to suggest further intervention scenarios.</p> <p>They were asked to consider recommendations, gaps in evidence, equity issues, terms for glossary and identifying experts to bridge the gaps.</p> <p>Howard Thomas left the meeting at 15.50pm.</p> <p>Action: NM to email the PDG asking them to prioritise possible intervention scenarios</p>	<p>NM/PDG</p>
<p>13. Next steps</p>	<p>Antony Morgan thanked the PDG for their work.</p> <p>The PDG were asked to let the NICE Team know if there are any further gaps within the evidence.</p> <p>Ann Mackie and Mike Lombard will be invited to attend the next meeting to discuss screening versus case finding.</p> <p>The NICE Team will help the PDG prepare for the next meeting in regards to writing recommendations.</p>	

15. AOB	There was no other business.	
14. Close	The meeting closed at 16.00pm	

Next meeting

PDG 6: 15th December 2011, Room Bollin, NICE Offices, City Tower,
Manchester
Papers to be emailed 2nd December, 2011